CJC-1295

CJC-1295 also causes the release of GH, but it does so by stimulating the growthhormone releasing hormone receptor, lt is also highly selective and has demonstratedpositive benefits on bone health, lean body mass, insulin resistance, and muscle growthand development[7]-[9]. By combing the two peptides, it may be possible to produceenhanced effects because they stimulate the growth hormone axis via two diferentmechanisms. Research in animal models using both peptides is likely to show increasedbenefit without substantially increased side effects.
Ipamorelin is likely to raise baseline levels of GH such that CJC-1295 will be able toproduce both higher peaks and higher troughs while preserving normal growth hormonepulsatile secretion. The net effect of combing the peptides would be a higher set point forthe normal ebb and flow of GH, resulting in improved lean body mass, better muscledevelopment, improved use of insulin, and overall better metabolic function.

About The Author

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. ELogan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific JournalAuthor

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistryfrom the University of Paris Xl, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R.Barton as Research Advisor. He completed his Post-Doctoral Research at the Universityof California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRFanalog and also held various leadership positions involving peptide research andtechnologies at lpsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon hasserved as a Director for Enobia (acquired by Alexion) and Neuronax and as a member ofthe Scientific Advisory Board of Syntaxin (acquired by lpsen) and Biosortia. Henow brings 30 years of executive and scientific leadership experience to the EpivaxOncology team.
Dr. Dominique Bridon is being referenced as one of the leading scientists involved in there search and development of CJC-1295. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. Dr.Dominique Bridon is listed in [10] under the referenced citations.

Resources

1.K. Raun et al., “lpamorelin, the first selective growth hormone secretagogue,” Eur.J.Endocrinol.,vol.139,no.5, pp.552-561,Nov. 1998.[PubMed]
2.N.B.Andersen, K. Malmlüf, P. B. Johansen, T. T. Andreassen, G. rtoft, and H.Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid.induced decrease in bone formation of adult rats,” Growth Horm. lGF Res. Off. J.Growth Horm.Res.Soc.Int.IGF Res.Soc.,vol.11,no.5, pp.266-272,Oct. 2001[PubMed]
3.J.Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6increase bone mineral content in adult female rats,” J.Endocrinol.. vol. 165. no. 3.pp.569-577,Jun.2000.[PubMed]
4.E.Adeghate and A.S. Ponery, “Mechanism of ipamorelin-evoked insulin releasefrom the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no.6,pp.403-406, Dec.2004.[PubMed]
5.D.E. Beck, W. B.Sweeney, M. D. McCarter, and lpamorelin 201 Study Group,“Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimeticipamorelin for the management of postoperative ileus in bowel resection patients.Int.J.Colorectal Dis., vol.29,no.12,pp.1527-1534, Dec.2014.[PubMed]
6.B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy ofipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model ofpostoperative ileus,”J.Exp.Pharmacol., vol.4, pp.149-165, Oct. 2012.[PubMed
7.M.Alba et al., “Once-daily administration of CJC-1295, a long-acting growthhormone-releasing hormone (GHRH) analog, normalizes growth in the GHRHknockout mouse,”Am.J.Physiol. Endocrinol. Metab., vol.291,no.6, pp.E12901294, Dec.2006.[PubMed]
8.M. lonescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH)persists during continuous stimulation by CJC-1295, a long-acting GH-releasinghormone analog,”J.Clin.Endocrinol. Metab., vol.91,no.12,pp.4792-4797, Dec2006.[PubMed]
9.M.C. Van Hout and E. Hearne, “Netnography of Female Use of the SyntheticGrowth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no.1, pp.73-84, Jan.2016.[PubMed]
10.Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille.Martin & Pellerin, lsabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan &Bridon, Dominique.(2005).hGRF1-29-Albumin Bioconjugates Activate the GRFReceptor on the Anterior Pituitary in Rats: ldentification of CJC-1295 as a LongLasting GRF Analog. [Research Gate]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.